Clinical Trial Update: A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating ABBV-105 alone or with Upadacitinib (ABBV-599) in active rheumatoid arthritis has completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ABBV-105
• ABBV-599
• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis (RA) | Phase 2 | Status: COMPLETED | Results posted: 2021-05-03